# Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

> **NCT03652233** · PHASE1 · WITHDRAWN · sponsor: **Vanderbilt-Ingram Cancer Center**

## Conditions studied

- Recurrent Squamous Cell Carcinoma of the Head or Neck
- Metastatic Squamous Cell Carcinoma of the Head or Neck
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT03652233
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11-02
- **Primary completion:** 2021-11
- **Final completion:** 2022-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2019-06-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652233, "Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03652233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*